Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.94) by 11.7 percent. This is a 25.76 percent decrease over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $18.265 million which missed the analyst consensus estimate of $18.513 million by 1.34 percent. This is a 29.47 percent increase over sales of $14.108 million the same period last year.